Role of D(T)PACE-based regimens as treatment of multiple myeloma with extramedullary relapse or refractory disease

Autor:	Mohamad Mohty, Nabaz Jaff, Laurent Garderet, Zora Marjanovic, Elise Corre, Paul Coppo, Simona Lapusan, Marie-Paule Lemonnier, Remy Dulery, Tony Huynh
Rok vydání:	2021
Předmět:	Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment 03 medical and health sciences 0302 clinical medicine Refractory Extramedullary Involvement Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans High activity Multiple myeloma Retrospective Studies Chemotherapy business.industry Hematopoietic Stem Cell Transplantation Refractory Disease Hematology medicine.disease Regimen Extramedullary disease 030220 oncology & carcinogenesis Neoplasm Recurrence Local Multiple Myeloma business 030215 immunology
Zdroj:	Leukemia & Lymphoma. 62:2235-2241
ISSN:	1029-2403 1042-8194
DOI:	10.1080/10428194.2021.1907373
Popis:	In multiple myeloma, atypical forms with extramedullary involvement exhibit poor survival. The poly-chemotherapeutic regimen D(T)-PACE has shown high activity in relapsed or refractory multiple myeloma. In this large monocentric retrospective study, we addressed the activity of D(T)-PACE-based regimens in 43 heavily pretreated patients with relapsed/refractory multiple myeloma and extramedullary disease.Median age at initiation was 57 years. Four patients had a t(4;14) translocation, 3 had a t(11;14) translocation and 7 had a del(17p). Extramedullary sites were mostly the skin (15 patients), central nervous system (10 patients), and thorax or abdomen (10 patients each). Overall response was achieved in 25 (58%) patients, including 6 (14%) with a complete response. Median progression-free survival was 5.0 months. Median overall survival was 9.0 months. Fourteen patients subsequently underwent stem-cell transplantation. Cytogenetics had no impact on response rate, overall survival and progression-free survival.In the era of several new immunotherapies, D(T)-PACE-based regimens still remain a useful treatment option for a selected group of heavily pretreated myeloma patients.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77198c040a3947eff0e148855b55fb31 https://doi.org/10.1080/10428194.2021.1907373 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.